CYP2C19 and gastric cancer: We selected the CYP2C19 polymorphism based on its serving as a predictive marker of the effectiveness of proton pump inhibitors (PPIs), lansoprazole, and omeprazole and because PPI-mediated eradication of Helicobacter pylori is a standard and preventive treatment for gastric cancer in Eastern Asia (26), (27).